All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On Monday 3 December 2018, Oral Session 626 took place at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. During that session, Abstract #781 with the results of the FLYER trial were presented by Viola Poeschel from Saarland University Medical School, Saarland, Germany.
In this phase III trial, the investigators hypothesized that four cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) plus two more rituximab infusions are similarly efficacious to the current standard of care for young non-Hodgkin lymphoma (NHL) patients, of six R-CHOP cycles. The primary endpoint of the trial was 3-year progression-free survival (PFS). Secondary endpoints included, response rates, event-free survival (EFS), overall survival (OS), and safety.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox